IP Library Granted Patent US 8,734,816
Granted Patent B2
US 8,734,816 · App. 13/143,164 · Granted May 27, 2014

Porous nanoparticle supported lipid bilayer nanostructures

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,734,816
App. No.
13/143,164
Granted
May 27, 2014
Kind
B2
Abstract

Various exemplary embodiments provide protocell nanostructures and methods for constructing and using the protocell nanostructures. In one embodiment, the protocell nanostructures can include a core-shell structure including a porous particle core surrounded by a shell of lipid bilayer(s). The protocell can be internalized in a bioactive cell. Various cargo components, for example, drugs, can be loaded in and released from the porous particle core of the protocell(s) and then delivered within the bioactive cell.

Claims (17)

1. A protocell nanostructure comprising:

a negatively charged porous silica particle core comprising a plurality of pores;

a non-negatively charged fused lipid bilayer on the surface of said porous particle core; and

a negatively charged cargo component which is loaded into said pores of said porous particle core by combining said cargo with non-negatively charged lipid when said lipid forms said lipid bilayer, wherein said particle core has a particle diameter ranging from about 30 nm to about 3000 nm and is capable of releasing said cargo from the porous particle core at a pH below 7.

2. The protocell nanostructure of claim 1 , wherein said cargo is a negatively charged chemotherapeutic drug or nucleic acid.

3. The protocell nanostructure of claim 2 , wherein said porous particle core comprises a polymer hydrogel particle or an inorganic particle.

4. The protocell nanostructure of claim 1 , wherein the lipid bilayer comprises a phospholipid selected from the group consisting of 1,2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP), 1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (DOPC) or a combination thereof.

5. The protocell nanostructure of claim 2 , wherein said lipid bilayer comprises 1,2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP).

6. The protocell nanostructure of claim 2 , wherein said lipid bilayer comprises 1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (DOPC).

7. The protocell nanostructure of claim 2 , wherein said lipid bilayer comprises a mixture of 1,2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP) and 1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (DOPC).

8. A delivery system for delivering a cargo component from a protocell nanostructure, said delivery system comprising a population of protocell nanostructures, each nanostructure comprising a negatively charged porous silica particle core comprising a plurality of pores, a non-negatively charged fused lipid bilayer on the surface of said porous particle core; and one or more negatively charged cargo components which are loaded into said pores of said porous particle core by combining said cargo with non-negatively charged lipid when said lipid forms said bilayer, wherein said particle core has a particle diameter ranging from about 30 nm to about 3000 nm and is capable of releasing said cargo from said porous particle core at a pH below 7.

9. The delivery system according to claims 8 , wherein said cargo is a negatively charged chemotherapeutic drug or nucleic acid.

10. The delivery system according to claim 8 , wherein said porous particle core comprises a polymer hydrogel particle or an inorganic particle.

11. The delivery system according to claim 8 , wherein the lipid bilayer comprises a phospholipid selected from the group consisting of 1,2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP), 1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (DOPC) or a combination thereof.

12. The delivery system according to claim 9 , wherein said lipid bilayer comprises 1,2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP).

13. The delivery system according to claim 9 , wherein said lipid bilayer comprises 1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (DOPC).

14. The delivery system according to claim 9 , wherein said lipid bilayer comprises a mixture of 1,2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP) and 1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (DOPC).

Assignments (9)
SANDIA'S PATENT PLEDGE AND AGREEMENT Recorded Jan 24, 2019
From: NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC
To: THE UNITED STATES OF AMERICA
Reel/Frame 048298/0292 →
CHANGE OF NAME Recorded May 22, 2018
From: SANDIA CORPORATION
To: NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC
Reel/Frame 046209/0521 →
CONFIRMATORY LICENSE Recorded Feb 20, 2015
From: SANDIA CORPORATION
To: U.S. DEPARTMENT OF ENERGY
Reel/Frame 035053/0771 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2014
From: CARNES, ERIC C.
To: THE REGENTS OF THE UNIVERSITY OF NEW MEXICO
Reel/Frame 032523/0617 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 030830 FRAME 0075. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST. Recorded Aug 15, 2013
From: STC. UNM
To: STC. UNM; SANDIA CORPORATION
Reel/Frame 031058/0210 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2013
From: STC.UNM
To: SANDIA CORPORATION
Reel/Frame 030830/0075 →
CONFIRMATORY LICENSE Recorded Apr 5, 2012
From: UNIVERSITY OF NEW MEXICO ALBUQUERQUE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027993/0920 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2011
From: ASHLEY, CARLEE ERIN; BRINKER, C. JEFFREY; LIU, JUEWEN
To: THE REGENTS OF THE UNIVERSITY OF NEW MEXICO C/O RESEARCH & TECHNOLOGY LAW
Reel/Frame 027300/0981 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2011
From: THE REGENTS OF THE UNIVERSITY OF NEW MEXICO C/O RESEARCH & TECHNOLOGY LAW
To: STC.UNM
Reel/Frame 027301/0466 →